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Abstract
The aim was to evaluate whether adjunctive T3 can help accelerate the antidepressant response and
improve overall outcomes when used under naturalistic conditions. Fifty consecutive psychiatric out-
patients diagnosed with major depressive disorder who were initiated on antidepressant therapy were
randomized to receive adjunctive T3 or placebo in a double-blind manner over the course of 6 wk. There
were no restrictions placed on the selection of antidepressant agent, dosing, ancillary medications, or
psychotherapy, and there were few exclusion criteria. A positive response was defined as a o50%
reduction in Montgomery–Asberg Depression Rating Scale scores. Response rates were higher for the
adjunctive T3 cohort compared to the adjunctive placebo cohort after 1 wk (45% vs. 24%) and 2 wk (57%
vs. 33%) of treatment. The likelihood of experiencing a positive response at any point over the 6-wk trial
was 4.5 times greater in the adjunctive T3 cohort (95% CI 1.3–15.7). The study provides preliminary
evidence that T3 can successfully be used in clinical practice to accelerate the antidepressant response and
improve overall outcomes. The effectiveness model may be an untapped mechanism for evaluating the
value of psychopharmacological agents.
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Introduction
Recent reports in both scientific journals and the media
have questionedwhether the benefits of antidepressant
medications have been exaggerated over the years
(Fisher and Greenberg, 1997 ; Goleman, 1995 ; Horgan,
1998 ; Kirsch and Sapirstein, 1999 ; Zimmerman et al.,
2002). It has been estimated, for example, that only
half of all antidepressant efficacy trials yield positive
results (Khan et al., 2002), while negative studies often
go unpublished. Even in the positive studies that
have been published, the benefits of antidepressant
somatic therapy appear to be only modestly better
than placebo (Fisher and Greenberg, 1997 ; Kirsch and
Sapirstein, 1999). If only modest results are achieved
in highly selected populations conducted under
rigorous conditions, how well can these medications
be expected to perform in the real world? The differ-
ences that exist between findings from controlled re-
search (efficacy) and treatment under naturalistic
conditions (effectiveness) has been termed the efficacy-
effectiveness gap. The importance to the field in
bridging this gap has been well elucidated (Bauer
et al., 2001 ; Wells, 1999), but to date little progress has
been made. Standard placebo-controlled trials have
rarely been conducted in naturalistic settings, perhaps
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because it is widely assumed that drug–placebo
differences would be obscured by multiple confound-
ing variables. A second concern might be that if a
treatment with proven efficacy cannot be shown to
be beneficial in usual clinical practice, a seemingly in-
tractable dilemma would arise as to whether that
treatment can be recommended.
The standard methodology used to demonstrate
antidepressant efficacy has evolved largely from tra-
dition, however, and there is little empirical evidence
suggesting that this methodology is efficient at elicit-
ing drug–placebo differences (Posternak et al., 2002).
Increasing attention has been paid recently to themany
shortcomings of the traditional design, and at least
seven features of the efficacy design may actually
serve to obscure drug–placebo differences. First, the
majority of antidepressant trials rely on the Hamilton
Depression Rating Scale (HDRS). Although the HDRS
represented a major advancement at the time it was
introduced by standardizing outcome ratings, its
shortcomings have been well enumerated: an over-
emphasis on sleep items, focus on many symptoms
peripheral to depression, and absence of items devoted
to reversed neurovegetative symptoms (Bagby et al.,
2005 ; Zimmerman et al., 2005). Second, most treatment
studies are carried out at multiple sites across the
country or world, and training of raters may be inad-
equate, with few published studies reporting or even
establishing inter-rater reliability (Mulsant et al., 2002).
Third, outcome ratings are conducted for the most
part by research assistants who lack the training, ex-
perience, and sophistication that a treating psychiatrist
would be expected to have. Poor training and weak
reliability increase error variance and could dramati-
cally reduce the ability to detect drug–placebo differ-
ences. Fourth, efficacy trials are conducted in artificial
settings and are offered as temporary treatment trials.
Subjects do not have the opportunity to develop a
rapport with a treating psychiatrist. Such dynamics
can be expected to lead to higher dropout rates, which
poses a significant obstacle to demonstrating drug–
placebo differences. Fifth, efficacy trials are often con-
ducted with strong financial incentives, and there may
be subtle or overt pressure to recruit subjects quickly.
Such an arrangement tends to lead to a relaxation of
entry requirements, and the baseline rating scores may
get inflated to ensure that subjects meet the minimum
symptom severity score requirement (Faries et al.,
1999 ; Robinson and Rickels, 2000). This introduces
further error variance. Sixth, dosing regimens tend
to be either fixed or restricted, and such restrictions
have been shown to reduce drug–placebo differences
(Khan et al., 2003). Seventh, clinical trials often require
subjects to present for in-person assessments on a
weekly basis. These assessments can take 15–30 min or
more – a significantly greater amount of contact than
occurs in usual clinical practice. This frequent contact
has been shown to have a significant therapeutic im-
pact (Posternak and Zimmerman, In Press), which can
further reduce drug–placebo separation. Finally, trial
investigators who collect outcome ratings are also
usually the same ones who inquire about side-effects,
and the occurrence of side-effects can ‘unblind’ ran-
domization (Greenberg et al., 1992). Although un-
blinding would probably increase rater bias in favour
of magnifying drug–placebo differences, this design
flaw further undermines the validity and trust in the
study’s results.
Thus, although it is possible that the benefits of
antidepressant medications have been exaggerated as
some have suggested, an alternative explanation is
that the traditional design used for evaluating anti-
depressant efficacy may not be an efficient mechanism
for separating active medication from placebo. If
so, the true benefits of antidepressant therapy may
actually be underestimated. Conducting randomized
trials in naturalistic settings would overcome many of
these methodological pitfalls, and although counter to
traditional teaching, could in theory demonstrate a
superior treatment effect. In addition, of course, effec-
tiveness research enjoys greater ecological validity and
generalizability.
A major obstacle to conducting effectiveness re-
search in naturalistic settings is that it can be difficult to
recruit subjects into placebo-controlled trials. Placebo-
controlled trials in private settings are most likely
to succeed if : (1) there is minimal burden placed on
patients and clinicians ; (2) the study poses minimal
deviation from standard clinical practice ; (3) patients
randomized to placebo receive treatment that ap-
proximates usual care ; and (4) preliminary evidence
exists supporting both the safety and efficacy of the
treatment intervention of interest.
An ideal candidate that meets each of these require-
ments is the use of L-triiodothyronine (T3) as an
adjunctive agent to antidepressant therapy for the
treatment of major depression. The antidepressant
properties of T3 have been recognized for over 30 yr
(Earle, 1970). Research has suggested that adjunctive
T3 may both hasten the antidepressant response
(Altshuler et al., 2001) (i.e. reduce the time to when
the antidepressant response occurs), and improve
outcomes in patients who have not responded to an
initial adequate antidepressant trial (Abraham et al.,
2006 ; Aronson et al., 1996). Of note, however, a re-
cent placebo-controlled study by Appelhof et al.
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(2004) found that T3 did not help accelerate the
antidepressant response when added to paroxetine,
nor did it improve response rates at end-point. As a
natural substance, T3 is considered to be one of the
safest psychopharmacological agents available. Never-
theless, despite modest empirical support, a favour-
able side-effect profile, and a generic formulation,
adjunctive T3 is rarely used in clinical practice (Byrne
and Rothschild, 1997; Chaimowitz et al., 1991 ;
Fredman et al., 2000 ; Shergill and Katona, 1997). The
reasons for the under-utilization of T3 are unclear, but
may stem from problems inherent in the T3 research
conducted to date. Limitations of most of this research
(other than and prior to the study by Appelhof et al.)
include small sample sizes (range 4–35 subjects), focus
on psychiatric in-patients rather than outpatients, and
a paucity of data with the newer generation of anti-
depressants (Lasser and Baldessarini, 1997).
The goals of the present study were therefore two-
fold: (1) to evaluate whether the results of the T3
research conducted to date – most of which was per-
formed over 25 yr ago – can be extended to today’s
practice ; and (2) to determine whether drug–placebo
differences can be elicited using an effectiveness rather
than efficacy trial design, thereby demonstrating the
benefits of a somatic intervention as it might be used
inusual clinical practice.Design featureswe implemen-
ted in the present study to enhance drug–placebo sep-
aration include: (1) using the Montgomery–Asberg
Depression Rating Scale (MADRS; Montgomery and
Asberg, 1979) as the primary outcome measure, and
validating all outcome ratings with a self-rated instru-
ment ; (2) having the treating psychiatrist conduct out-
come ratings ; (3) conducting all assessments at a single
site after demonstrating strong inter-rater reliability
among all raters ; (4) conducting the trial in a natural-
istic setting, which we hypothesize will lead to lower
dropout rates ; (5) allowing flexible dosing schedules ;
(6) assessing side-effects only after outcome ratings had
been collected ; and (7) absence of financial incentives.
Method
All subjects were recruited from the Rhode Island
Hospital Department of Psychiatry’s outpatient prac-
tice. This is a fee-for-service practice that functions
independently from the Brown University Residency
Program. At the time of presentation and prior to
meeting their treating clinician, patients were invited
to undergo a research diagnostic evaluation as part of
the Rhode Island Methods to Improve Diagnostic As-
sessment and Services (MIDAS) project (Zimmerman
and Mattia, 1999, 2000). This evaluation consists of the
Structured Clinical Interview for DSM-IV (SCID; First
et al., 1997) and the Structured Interview for DSM-IV
Personality Disorders (SIDP-IV; Pfohl et al., 1997), as
well as various other clinician- and patient-rated in-
struments. This evaluation is most often conducted by
clinical psychologists who have undergone extensive
training. Fifteen subjects treated by either Dr Posternak
or Dr Zimmerman who did not participate in the
MIDAS project were also recruited. For these in-
dividuals, Axis I diagnoses were established using
the Psychiatric Diagnostic Screening Questionnaire
(PDSQ; Zimmerman and Mattia, 2002), followed by a
clinical evaluation by the treating psychiatrist. The
presence of borderline personality disorder (BPD) was
evaluated in this group using the BPD component of
the SIDP-IV. No baseline demographic or clinical dif-
ferences were found between subjects who did and
did not undergo a research diagnostic evaluation.
Eligibility criteria for the study included being aged
at least 18 yr and meeting full DSM-IV criteria for
major depressive disorder (MDD). Subjects who had
unstable cardiac, endocrine, or renal disease, a history
of thyroid disease, or an abnormal baseline thyro-
tropin (normal range 0.3–5.5 uIU/ml), were excluded.
Other than medical contraindication to T3 therapy,
however, there were no restrictions to participation.
Thus, patients diagnosed with bipolar disorder, psy-
chotic features, psychiatric comorbidity, or a history
of treatment resistance, were all invited to participate.
The trial was designed as a pilot effectiveness study
to establish feasibility and to evaluate whether drug–
placebo differences could be elicited using this model.
As such, a sample size of 50 subjects was targeted. The
study was therefore not powered to find significant
differences. With a sample size of 25 subjects per co-
hort, and an estimated effect size of 0.6 (Altshuler et al.,
2001), there was approximately a 55% chance of ob-
serving significant differences between groups. The
protocol was approved by the Rhode Island Hospital
Institutional Review Board and all subjects provided
informed, written consent.
Consecutive subjects were recruited at the time an
antidepressant medication was initiated. The present
study therefore focuses on the ability of T3 to accelerate
(reduce the delay in time to response) and potentiate
(improve outcomes at end-point) the antidepressant
response, but does not evaluate T3 as an augmentation
agent for treatment non-responders. All treatment,
except for adjunctive T3 and placebo, was open label
and followed usual clinical practice. No restrictions
were placed on the selection of antidepressant, dosage,
ancillary medications, or psychotherapy. The anti-
depressant agent was not changed during the course
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of the 6-wk trial. All participating subjects were
randomized to receive either adjunctive T3 at a dose
of 0.025 mg/d or placebo in identically appearing
capsules each morning in a double-blind manner over
the course of 6 wk. We chose the lower 0.025 mg/d
dosage as opposed to the 0.05 mg/d dosage, because
this has become more commonly used in prior re-
search. Randomization was accomplished by having
the pharmacist pre-sort study pills, and allowing the
treating clinician to randomly pick coded vials to give
to a study subject at the time of recruitment. The study
medication was typically initiated on day 2 rather than
day 1 because subjects were instructed not to take the
study pill until the baseline thyrotropin was confirmed
to be within the normal range. Compliance was not
formally monitored.
The primary outcome measure was the MADRS.
We chose the MADRS over other instruments because
it is relatively brief, and may be more sensitive to
change than the HDRS. Inter-rater reliability for the
MADRS and was established in 30 joint interviews.
The intra-class correlation coefficient for these inter-
views was 0.96. The self-rated Clinically Useful De-
pression Outcome Scale (CUDOS; Zimmerman et al.,
2004b) was used as a secondary outcome measure.
The CUDOS was chosen because it is brief, it is di-
rectly tied to DSM-IV, it assesses reversed neuro-
vegetative symptoms, and it is has a validated cut-off
for remission (a CUDOS score of <20) (Zimmerman
et al., 2004b). Antidepressant treatment history was
elicited using the Treatment Response to Antide-
pressant Questionnaire (TRAQ). The TRAQ is a semi-
structured instrument developed by our group with
demonstrated reliability (Posternak et al., 2004) and
validity (Posternak and Zimmerman, 2003).
Outcome ratings were collected by the treating
psychiatrist at baseline, weeks 1, 2, 3, and 6. Ratings
for weeks 1-3 focused on the putative ability of T3 to
accelerate the antidepressant response, while week 6
ratings focused on the ability of T3 to potentiate the
antidepressant response. In-person follow-up appoint-
ments were typically scheduled at week 3 and week 6
(although there were no restrictions on this), con-
sistent with our prior research (Posternak and
Zimmerman, 2001). Because participating subjects
were not reimbursed for their participation, it was
deemed overly burdensome to require them to present
for weekly visits. Therefore, MADRS and CUDOS
ratings for weeks 1 and 2 were usually conducted by
telephone. Telephone ratings have been demonstrated
to yield reliable and valid results (Mundt et al., 2006).
Side-effects to T3 therapy were assessed at week 3
and week 6 using a standardized hyperthyroid
checklist (Braverman and Utiger, 2000), which was
filled out after all other outcome ratings had been ob-
tained. At week 6, subjects and clinicians were asked
to guess on a 5-point scale whether they were ‘almost
sure’ or believed they ‘probably’ had received T3 (or
placebo), or whether they were ‘not sure’ which study
pill they had received.
Our two principal hypotheses were that (1) adjunc-
tive T3 will accelerate the antidepressant response
from baseline to week 3, and (2) adjunctive T3 will
improve overall response rates at end-point. To test
both hypotheses, we conducted categorical (i.e.
whether subjects achieved a o50% reduction in base-
line MADRS scores) and dimensional (i.e. mean
change) analyses. We used the Generalized Estimating
Equation (GEE) approach to evaluate the first hypo-
thesis regarding the ability of T3 to accelerate the
antidepressant response during the first 3 wk of treat-
ment (Diggle et al., 1994 ; Liang and Zeger, 1986 ; Zeger
and Liang, 1986). This method was chosen because
it adjusts the variance components of the parameter
estimates, which can become underestimated in the
presence of correlated data. This is particularly rel-
evant for longitudinal data where the within-subject
correlations are increased due to repeated measure-
ments collected on the same set of individuals over
time. However, we also report the score x2 test statistic
for each statistical test (e.g. Z statistic), which has been
shown to be more conservative than those based
on the empirical and model-based standard errors,
and is preferred for small samples (Stokes et al., 2000).
The estimates of the standard errors, which are
model-based, were derived from unstructured work-
ing correlational matrices given the relatively few
number of data-points per subject. The general model





=m+a * Treatment+b *Weeks
+d * (Treatment *Weeks),
where a is the main effect of Treatment status
(0=control, 1=T3), b is the main effect of time, as
measured in weeks (1, 2 and 3), and d is the interaction
between Treatment and Weeks. We also reformulated
this model to accommodate a continuous distribution
based on the raw scores of the MADRS for each week.
The baseline wave was also included in this model,
which consequently included four waves of data and a
4-level time-varying covariate for weeks (0, 1, 2, and 3).
Tests of the hypotheses concerning the main effect
of the intervention within each week and at end-point
were conducted using the standard logistic regres-
sion model for the binary outcomes (Hosmer and
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Lemeshow, 2000). Analysis of covariance (ANCOVA)
was used for the dimensional analyses to estimate
difference in treatment effects with the baseline
MADRS scores as covariates, using the last obser-
vation carried forward (LOCF). Remission from de-
pression was defined as an end-point MADRS score of
f10 (Zimmerman et al., 2004a).
Results
Recruitment and baseline characteristics
Eighty-nine subjects with MDD were initiated on
an antidepressant medication during the study period.
Of these, 16 subjects were excluded (most due to
medical comorbidity), and 16 others declined to par-
ticipate (see Figure 1). The remaining 57 subjects
were randomized to a study medication. Of these,
seven were withdrawn or dropped out prior to the
week 1 follow-up visit. No differences were found in
baseline features between subjects who did and did
not participate. Of the 50 subjects who participated
in the trial, 23 were randomized to adjunctive T3 and
27 to placebo. There were no statistically significant
differences in any of the baseline demographic or
clinical features between these two cohorts (Table 1).
Treatments received
Selective serotonin reuptake inhibitors (SSRIs) con-
stituted the majority of antidepressant prescriptions
(n=26, 52%), followed by bupropion (n=8, 16%),
venlafaxine (n=7, 14%), and mirtazapine (n=4, 8%)
(Table 2). All subjects except one received what is
generally considered a minimum adequate dosage
(Sackeim et al., 1990) (that one subject had responded
to 100 mg/d nefazodone, and the dosage was not
increased further because she also experienced side-
effects). Thirty-two (64%) subjects received one or
more ancillary medications during the course of their
treatment trial : 19 (38%) received a sedative-hypnotic,
16 (32%) an anxiolytic medication, three (6%) an
antipsychotic, one (2%) a mood stabilizer, and one
(2%) a stimulant. Ancillary medications were initiated
Patients initiated
on AD (n=89)
Not invited  (n=16)
4 Diabetes
4 Lack of time
3 Cardiac history
2 Thyroid disease
2 Unstable medical conditions
1 Lack of insurance
Invited to  participate
(n=73)
Declined to participate (n=16)
5 Did not want to be in a study
5 Did not want to take 2nd med
4 Did not want to get lab test
2 Concerned about side-effects
Withdrawn from study (n=7)
4 Did not get lab test
2 Did not return for follow-up
1 Non-compliant with study med
Randomized to T3 (n=23) Randomized to placebo (n=27)




or placebo  (n=57)
Figure 1. Flow chart of enrolment of subjects.
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(rather than continued) for 7/23 (30%) subjects ran-
domized to T3 compared to 15/27 (56%) subjects
randomized to placebo (x2=3.2, d.f.=1, p=0.07, n.s.).
Twenty-five (50%) subjects received at least one
psychotherapy session during the course of their
treatment trial. Eleven (22%) subjects initiated
psychotherapy and 14 (28%) were continued in
psychotherapy. Subjects randomized to placebo re-
ceived a greater number of psychotherapy sessions
(1.9¡2.1) than those randomized to T3 (0.6¡0.8)
(t=2.7, d.f.=35.4, p=0.007). There were no other stat-
istically significant differences between the two co-
horts in treatments received.
Forty-two of the 50 (84%) subjects completed the
6-wk trial : 19/23 (83%) subjects receiving adjunctive
T3 and 23/27 (85%) subjects receiving placebo com-
pleted the trial. As hypothesized, the retention rate
for patients in the present study was significantly
greater (x2=9.59, d.f.=1, p=0.002) than the 62.7%
rate reported in a recent meta-analysis of anti-
depressant trials (Posternak and Zimmerman, 2005).
Treatment response
Acceleration
Response rates were non-significantly higher accord-
ing to the MADRS during each of the first 3 wk of
treatment in the adjunctive T3 cohort compared to
the control group: week 1, 45% vs. 24%; week 2, 57%
vs. 33%; and week 3, 43% vs. 24%. The GEE model
evaluating dichotomous outcomes of response for
weeks 1–3 revealed no significant main effects for
condition (z=1.47, p=0.14), week (z=0.82, p=0.41), or
the interaction (z=0.02 ; p=0.99). An analysis evalu-
ating continuous outcomes (Figure 2) revealed a sig-
nificant effect favouring T3 over the first 3 wk of
treatment (z=2.0, p<0.05). The mean MADRS scores
for the T3 cohort over weeks 1–3 were 18.4 (S.D.=10.3),
14.0 (S.D.=9.4), and 17.2 (S.D.=13.0). ThemeanMADRS
scores for the adjunctive placebo cohort during the
same time-frame were 22.3 (S.D.=12.5), 23.5 (S.D.=
14.2), and 21.1 (S.D.=13.6), respectively. Differences in
MADRS scores reached statistical significance only at
week 2.
When outcomes were examined using the self-rated
CUDOS instrument, a similar pattern of improvement
was observed, although these differences did not reach
statistical significance (Figure 3). In both the self-rated
and clinician-rated instruments, both groups demon-
strated a slight increase in depression severity scores
at week 3. We are unclear as to why this might be, but
suspect that it is due to random variation that some-
times occurs when small sample sizes are employed.
Table 1. Baseline demographic and clinical features of T3





Female, n (%) 13 (57) 19 (70)
Age (yr), mean¡S.D. 40¡9.4 36¡11.4
Race : white, n (%) 21 (91) 24 (89)
Marital status, n (%)
Single 7 (30) 10 (37)
Married/living together 11 (48) 11 (41)
Divorced/separated/widowed 5 (22) 6 (22)
Education, n (%)
Less than high-school diploma 1 (4) 1 (4)
High-school graduate or GED 14 (51) 19 (70)
College or postgraduate degree 8 (40) 7 (26)
Antidepressant status
Newly initiated antidepressant 15 (65) 18 (67)
Switch following non-response 6 (26) 5 (19)
Switch following relapse 2 (9) 4 (15)
Episode duration (months) 51¡80 27¡37
Depression subtype
Unipolar MDD 20 (87) 21 (78)
Bipolar disorder, I or II 3 (13) 3 (11)
MDD with psychotic features 0 (0) 3 (11)
Comorbidity
No psychiatric comorbidity 6 (26) 3 (11)
Panic disorder¡agoraphobia 5 (22) 8 (30)
Post-traumatic stress disorder 5 (22) 3 (11)
Obsessive–compulsive disorder 1 (4) 2 (7)
Generalized anxiety disorder 10 (44) 11 (41)
Social phobia 7 (30) 4 (15)
Dysthymia 1 (4) 1 (4)
Eating disorder 1 (4) 4 (15)
Alcohol or drug abuse 2 (9) 6 (22)
Borderline personality disorder 3 (13) 4 (15)
Antidepressant treatment history
No prior adequate trials 7 (30) 7 (26)
1 failed adequate trial 4 (17) 6 (22)
2 failed adequate trials 1 (4) 2 (7)
o3 failed adequate trials 3 (13) 2 (7)
o1 positive trials 1 (4) 5 (19)
Some pos. and some neg. trials 7 (30) 5 (19)
Baseline MADRS 29.3¡7.6 30.3¡8.7
Baseline CUDOS 36.9¡9.8 39.7¡8.6
Baseline thyrotropin level 1.5¡0.7 1.5¡0.8
GED, General equivalency diploma; MDD, major
depressive disorder ; MADRS, Montgomery–Asberg
Depression Rating Scale ; CUDOS, Clinically Useful
Depression Outcome Scale.
a No statistically significant differences in baseline features
between the two cohorts.
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Antidepressant, n (median dosage for
week 3/week 6)
Fluoxetine 3 (20/40 mg) 9 (20/20 mg)
Sertraline 6 (50/50 mg) 2 (50/75 mg)
Escitalopram 3 (10/15 mg) 3 (10/20 mg)
Venlafaxine XR 5 (75/150 mg) 2 (150/150 mg)
Mirtazapine 1 (30/45 mg) 3 (15/30 mg)
Bupropion 3 (200/200 mg) 5 (200/350 mg)
Phenelzine 0 (0/0 mg) 1 (45/45 mg)
Nefazodone 1 (600/600 mg) 1 (100/100 mg)
Amitriptyline 1 (125/150 mg) 0 (0/0 mg)
Imipramine 0 (0 mg) 1 (150/150 mg)
Ancillary psychiatric medications
Sedative/hypnotics 8 (27) 11 (31)
Anxiolytics 7 (18) 9 (31)
Mood stabilizers 0 (0) 1 (6)
Stimulants 0 (0) 1 (6)
Antipsychotics 0 (0) 3 (19)
Initiated o1 ancillary medications 6 (26) 12 (44)
Psychotherapy
Received 1 or more therapy sessions 9 (39) 16 (59)
Initiated psychotherapy 5 (22) 6 (22)
Continued in psychotherapy 4 (17) 10 (37)
Number of therapy sessionsa (mean¡S.D.) 0.6¡0.8 1.9¡2.1






























1 4 5 6 7
Figure 2. Time-course of improvement on adjunctive T3 (–2–) and placebo (- -&- -). p values for ANCOVA tests
within weeks 1, 2, 3, and 6 control for baseline values of MADRS (weeks 4 and 5 imputed).
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Potentiation
At end-point, with LOCF, response rates were higher
for subjects receiving T3 than placebo (61% vs. 52%),
although this difference was not statistically significant
(OR 1.44, 95% CI 0.46–4.46, p=0.52). Remission rates
were also numerically higher according to both the
MADRS (48% vs. 37%) and CUDOS (55% vs. 33%),
although again these differences did not reach stat-
istical significance (p=0.44 and p=0.14, respectively).
Side-effects
Side-effects were assessed using an 11-item self-rated
checklist assessing symptoms consistent with hyper-
thyroidism (Table 3). For 10 out of 11 of these side-
effects, incidence rates were numerically higher in the
cohort receiving placebo. The only statistically signifi-
cant difference occurred for reports of nervousness,
which was significantly more common in the cohort
receiving placebo (10/22, 45%) than in the T3 cohort
(2/19, 11%) (x2=6.0, d.f.=1, p=0.01). Other studies
(e.g. Appelhof et al., 2004) have found that T3 does
induce a consistent and predictable side-effect profile.
Our inability to elicit side-effects may again be a
function of the small sample size employed.
Blinding
At the conclusion of the trial, subjects and clinicians
were asked to make a guess as to randomization as-
signment along with degree of conviction. Two-thirds
of all subjects reported that they were not sure which
assignment they had received. In the placebo cohort,
2/23 (9%) subjects thought or were almost sure they
were receiving T3, while 3/23 (13%) thought theywere
receiving placebo. In the T3 cohort, 5/19 (26%) thought
or were almost sure they were receiving T3, while
4/19 (21%) thought they were receiving placebo.
From the clinician standpoint, of 23 subjects ran-
domized to placebo, clinicians reported thinking that
six (26%) were receiving T3 and judged 2/23 (9%) to
be receiving placebo. In 20 subjects receiving T3, clin-
icians guessed correctly in seven (35%) instances and
incorrectly in four (20%) instances. In the remaining
instances, clinicians were unsure as to randomization.
Discussion
Traditionally, the therapeutic effects of a medication
are established under highly controlled conditions de
signed to maximize the likelihood of eliciting drug–
placebo differences. In antidepressant trials, subjects
with mild depression, a history of treatment resist-
ance, or psychiatric comorbidity are routinely ex-
cluded. Ancillary treatments are usually prohibited or
restricted in order to eliminate potential confounding
variables. Once efficacy is established under these
conditions, effectiveness is inferred for patients treated
in the real world. This inference cannot be assured,
however, because treatment conditions are distinct































1 2 3 4 6 75
Figure 3. Time-course of improvement on adjunctive T3 (–2–) and placebo (- -&- -). p values for ANCOVA tests
within weeks 1, 2, 3, and 6 control for baseline values of CUDOS (weeks 4 and 5 imputed).
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from those who participate in treatment studies
(Zimmerman et al., 2002). Ideally, the effectiveness
of all psychopharmacological agents could be estab-
lished under naturalistic conditions, but conducting
controlled trials in real-world settings presents mul-
tiple pragmatic obstacles. The lack of research under
naturalistic conditions has led to questions as to the
true effectiveness of psychopharmacological agents
in actual clinical practice (Zimmerman et al., 2002).
Psychotherapy researchers have already begun to
establish that findings from controlled psychotherapy
research can be exported to naturalistic settings
(Franklin et al., 2000 ; Persons and Silverschatz, 1998 ;
Wade et al., 1998), but we are not aware of any com-
parable attempts in psychopharmacology. A placebo-
controlled augmentation trial with T3 seemed to be
an ideal starting point to help bridge the efficacy-
effectiveness gap. T3 is well-tolerated, safe, and has
preliminary empirical support. Using an augmen-
tation paradigm, subjects who were randomized to
placebo received the same treatment they would
have had they not participated in the study (except for
the placebo pill). To the best of our knowledge, the
present study is first to directly evaluate whether
the specific benefits of a psychopharmacological
agent can be demonstrated while used under almost
entirely naturalistic conditions. Such conditions also
potentially allow for a much richer evaluation of the
study population, including rigorous assessments of
comorbidity and treatment history. Larger studies
could utilize such data to perform sub-analyses of
predictors of response that have heretofore rarely
been attempted.
Even without preferentially recruiting subjects who
might be more likely to respond to T3 or placing
restrictions on ancillary treatment, our results are sug-
gestive that adjunctive T3 may help accelerate the anti-
depressant response in clinical practice, and perhaps
improve overall outcomes. The benefits of T3 were
most apparent early in treatment, although separation
from the control group persisted to end-point. These
results must be viewed cautiously, however, since the
present study employed a relatively small sample size
and many of the differences did not reach statistical
significance. The present study must therefore be
viewed only as pilot in nature. We also can not rule out
that baseline differences – such as less psychiatric co-
morbidity in the T3 group – might have been at least
partially responsible for the drug–placebo separation.
Nevertheless, our ability elicit even some drug–
placebo separation under naturalistic conditions
with only modest sample sizes and without even at-
tempting to control for potential confounding factors
is encouraging on three counts. First, it provides
further evidence that T3 can be used to help accelerate
the antidepressant response, and may improve re-
sponse rates at the conclusion of a 6-week trial.
Second, our results provide preliminary evidence that
findings from controlled research may be able to be
replicated when conducted under naturalistic condi-
tions. Third, our study raises the possibility that
naturalistic settings may offer an untapped paradigm
to evaluate drug efficacy. Innovations that we made to
attempt to overcome potential obstacles present in
traditional research were: utilizing the MADRS as
opposed to the HDRS, having the treating psychiatrist
conduct all outcome ratings after demonstrating
strong inter-rater reliability, conducting the study en-
tirely at one site, allowing for flexible dosing, reducing
the amount of contact with the research clinician (to
minimize the non-specific therapeutic effects of such
interactions), and a lack of financial incentives.
Although it is impossible to determine what impact
these factors had on outcomes, the present study at
least demonstrated the feasibility of conducting
placebo-controlled research in clinical settings, while
obtaining high recruitment and retention rates.
Considering the enormous costs and consequences
of employing a potentially inefficient study design to
evaluate drug efficacy, it is surprising that more effort
has not gone into studying the impact of various
design features. In addition to overcoming many
of the pitfalls that are present in traditional efficacy
studies, controlled research in naturalistic settings is
undoubtedly the best way to gauge the true value of a
psychopharmacological intervention.
Table 3. Side-effects reported in the adjunctive T3
and placebo cohorts
T3 (n=19) Placebo (n=22)
Nervousnessa 2 (11%) 10 (46%)
Fatigue 4 (21%) 7 (32%)
Weakness 3 (16%) 4 (18%)
Increased sweating 2 (11%) 6 (27%)
Heat intolerance 4 (21%) 1 (5%)
Tremor 0 (0%) 2 (9%)
Hyperactivity 1 (5%) 2 (9%)
Palpitations 2 (11%) 3 (14%)
Appetite increase 2 (11%) 3 (14%)
Weight decrease 2 (11%) 7 (32%)
Menstrual disturbancesb 0 (0%) 1 ( 4%)
a Statistically significant (x2=6.0, d.f.=1, p=0.01).
b Based on subsample of women for T3 (n=9) and
placebo (n=14).
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Further research is warranted to confirm that T3
can help accelerate the antidepressant response in
clinical practice and improve overall response rates.
Even a modest augmentation in response rates could
have an enormous public health impact. Positive re-
sults could also help instil confidence in using an ef-
fectiveness model for evaluating the benefits of other
psychopharmacological agents.
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